REG - Allergy Therapeutics - Pledge of Shares
RNS Number : 9787RAllergy Therapeutics PLC11 March 2021
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Pledge of Shares
Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, announces that, on 10 March 2021, it was notified that Manuel, Llobet, Chief Executive Officer and PDMR, entered into a personal loan agreement on 9 March 2021, whereby security over 1,125,000 ordinary shares of 0.01 pence each in the capital of the Company was granted in favour of Banco Santander.
There is no change in Mr Llobet's beneficial shareholding in the Company and he continues to have an interest and voting rights in 3,325,000 ordinary shares, representing approximately 0.52% of the issued share capital of the Company.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Manuel Llobet
2
Reason for the notification
a)
Position/status
Manuel Llobet - Chief Executive Office and PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ALLERGY THERAPEUTICS PLC
b)
LEI
LEIR97215202003301009534776
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary Shares
b)
Identification code
GB00B02LCQ05
c)
Nature of the transaction
Mr Llobet entered into a personal loan agreement with Banco Santander whereby security over 1,125,000 ordinary shares in the Company. Mr Llobet remains the beneficial owner of the shares subject to the pledge and retains full voting rights.
d)
Price(s) and volume(s)
Price(s)
Volume(s)
n/a
1,125,000
e)
Aggregated information
n/af)
Date of the transaction
9 March 2021
g)
Place of the transaction
Outside a trading venue
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Ashley Tapp / Olivia Manser
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines, that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved double digit compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHBDGDXCGBDGBB
Recent news on Allergy Therapeutics
See all newsREG - Allergy Therapeutics - Update on funding
AnnouncementREG - Allergy Therapeutics - Update on funding and preliminary results
AnnouncementREG - Allergy Therapeutics - Progression of patient cohorts in PROTECT Trial
AnnouncementREG - Allergy Therapeutics - Update on funding
AnnouncementREG - Allergy Therapeutics - Trading update for the year ended 30 June 2024
Announcement